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Abstract
Background: Podocalyxin (podxl) is a heavily glycosylated transmembrane protein mainly found
on the apical membrane of rat podocytes and also in endothelial, hematopoietic, and tumor cells.
Despite of its interest no much is known about the transcriptional regulation of podxl in different
cells. Thus, we aimed at studying the functional features of the 5'-regulatory region of the human
Podxl gene.
Results: The promoter region of the human Podxl gene has been cloned and its structure and
function were analyzed. The primary DNA sequence is rich in G+C and is devoid of TATA or
CAAT boxes. The sequence contains recognition sites for several putative transcription factors;
however, the basic promoter activity seems to rely entirely on Sp1 transcription factor since
supershift analysis was positive only for this factor. The region encompassed by 66 to -111 nts
conferred the minimal transcriptional activity that increases as the number of Sp1 sites augmented
with the length of the promoter fragment. In Sp1-lacking insect cells the Podxl promoter constructs
showed activity only if cotransfected with an Sp1 expression plasmid. Finally, mutation of the Sp1
sites reduced the promoter activity.
We analyzed whether methylation of the CpG dinucleotides present in the first ~600 nts of the
promoter region of Podxl could explain the variable rates of expression in different types of cells.
Inactivation of methyltransferases by 5'-aza-2'deoxicitidine showed a dose-dependent increase in
the podxl content. Moreover, in vitro methylation of the promoter constructs -111,-181 and -210
led to an almost complete reduction of the promoter activity. A correlation was found between
the degree of methylation of the CpG promoter dinucleotides and the rate of podxl expression in
different cell lines.
Conclusion: Our results indicate that transcriptional regulation of Podxl is supported primarily by
Sp1 site(s) and that DNA-methylation of the CpG promoter islands contributes to control the
tissue specific expression of podxl.
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Background
Podocalyxin (podxl) is an integral membrane protein
originally identified by Kerjaschki et al [1] in the foot
processes of the rat kidney glomerular podocytes. It was
described as a sialoprotein of 140-kDa based on its stain-
ing with alcian blue. The high sulfate content of this pro-
tein contributes in part to its heavily negative charge [2]
that is supposed to maintain open the interdigitations of
the podocyte foot for the urine filtration. The importance
of the negative charge of this protein is indicated by the
loss of the structure and function of the podocytes by
treatment with polycations or desialylation with neurami-
nidase [3,4]. Null mice for podxl die soon after birth due
to failure to develop foot processes in the glomerular epi-
thelial cells [5]. Podxl like proteins have been cloned from
the rabbit, human, chicken and mouse [6-9].
The podxl is also expressed in the luminal face of the vas-
cular endothelia, hematopoietic cells and platelets
[10,11], among other tissues. The function of this protein
in non-renal cells has not yet been elucidated. It has been
suggested that it may function as a ligand for leucocyte
adhesion molecule L-selectin [12] due to its location in
the postcapillary venules of the lymph node, high
endothelial venules, and the fact that most of the L-selec-
tin ligands in the vascular endothelium are sialomucins.
Thus, the podxl of the vascular endothelia may contribute
to the migration of lymphocytes toward the lymph nodes.
The podxl proteins show a poorly conserved aminotermi-
nal, extracellular, mucin-like domain containing multiple
N- and O-linked glycosylation sites, a disulfide containing
domain and conserved transmembrane and cytoplasmic
domains. The cytoplasmic tails showed the highest iden-
tities among these proteins and interaction with cytosolic
proteins have been reported. Based on structural similari-
ties and their high content in sialic acid, Sassetti et al [13]
proposed that CD34, podxl and endoglycan, would form
a family named the CD34 family of sialomucins. The
three proteins are found in the vascular endothelia and
also in early hematopoietic precursors, suggesting that
their function may go from either cell anti-adherence, as it
is the case in the renal podocytes, to selective adherence or
control of cellular differentiation.
Despite the interest of podxl no much is known about the
transcriptional regulation of its gene in different cells. The
binding of the Wilms Tumor suppressor factor (WT1) to
conserved elements within the Podxl gene promoter
results in a potent transcriptional activation [14] that
seems to be relevant only for the induction and develop-
ment of the kidney; however, a detailed analysis of the
human Podxl promoter (Podxl-pr) has not yet been per-
Transient transfection of deletion mutants of the 5'-flanking region of the human podocalyxin gene Figure 1
Transient transfection of deletion mutants of the 5'-flanking region of the human podocalyxin gene. Description 
of the construction of the pGL3-Podxl-pr reporter plasmids and transient transfection experiments are described under 
"Methods". Luciferase activity was corrected for transfection efficiency with the values obtained with Renilla and was expressed 
as percent of the maximal activity of the -364 construct. The results are mean ± SEM of three experiments performed in dupli-
cates.BMC Molecular Biology 2006, 7:17 http://www.biomedcentral.com/1471-2199/7/17
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formed. In the present study we have further characterized
the 5' regulatory region of this gene. We found absence of
a TATA-box and a transcriptional regulation supported
primarily by Sp1 site(s). In addition, the role of cytosine
methylation of the promoter region has been analyzed to
elucidate whether this epigenetic mechanism might con-
tribute to control the specific regulation of the expression
of this gene.
Results
Features of the 5' flanking region of the human 
podocalyxin
The human Podxl gene and 250 bps upstream of the puta-
tive start methionine was previously cloned and mapped
to chromosome 7q32-q33 by Kershaw et al [7,15]. We
amplified by PCR a 1528 bp-DNA fragment of the 5' reg-
ulatory region of the human Podxl gene comprising 1297
bp from the transcription start site plus 231 bp of 5'-
untranslated region, using the primers sense: -1297/-1275
and antisense: 231/208. We started numbering from the
transcription start site [GenBank:AF395890]. Computer
analysis using the software "Transcription Factor Binding
Site Profile Database" (TFSEARCH program) [16],
revealed a high G+C content of the proximal promoter
region and a lack of CCAAT and TATA-like elements, a fea-
ture commonly found in the house-keeping genes. We
also detected potential binding sites for the transcription
factors AP2 (-247/-236 and -114/-93 nts) (two overlapped
sites); overlapped Sp1 sites (167/-140, -146/-128 and -91/
-68 nts); overlapped Sp1 and AP2 sites (-279/-266 nts),
overlapped Sp1 and NFKB sites (-204/-189 nts), three
GATA-1 sites (-1138/-1129, -1057/-1051 and -444/-435
nts) and three WT-1 sites (two overlapped at -1233/-1216
and one at -507/-498 nts).
To determine the location of the promoter activity we
studied the transcriptional activity of chimeric constructs
of progressively 5'-deleted DNA fragment (-1297/231)
linked to the luciferase (pGL3) reporter (Fig. 1). The con-
structs were transiently transfected into Tera-1, HEK293
and HepG2 cells, which podxl content differs considera-
bly (Fig. 2). Figure 1 depicts the results obtained with the
three types of cells. No significant transcriptional activity
was detected with the fragment of +66 bp. The activity
started on construct -111, increasing with the length of the
fragment up to -364. Thus, the basal promoter activity is
located within the -111 to +66 bp region, whereas the
upstream 253 bp confers maximal transcriptional activity.
The extension of the 5' flanking sequence up to -1297
diminished the promoter activity. All cells expressed sim-
ilar amounts of Sp1 (Fig. 2, middle row).
Regulatory role of Sp1 on Podxl promoter activity
The fragments up to the first 364 bp show a progressive
increasing number of Sp1 sites, suggesting their role in
transcription. To test this possibility we transfected some
of the constructs into the Sp1-deficient Drosophila-
derived Schneider's SL2 cells. As indicated in Fig. 3, no
transcriptional activity could be detected when the con-
structs +66, -111, -181,-210 and -364 were transfected
into these cells; however, the transcriptional activity was
initiated in all the constructs, except for the +66, when the
cells were cotransfected with a plasmid expressing Sp1
(Fig. 3). Thus, the Sp1sites seem to be essential to main-
tain a normal basal rate of transcription of Podxl.
The DNA/protein interactions were characterized by elec-
trophoretic mobility of DNA-protein complexes (EMSA).
The assays were performed with two different probes
encompassing the -243/-18 and -538/-238 Podxl frag-
ments and nuclear extracts from cells with either low or
high levels of podxl expression (Meg0l and Tera-1 cells,
respectively, Fig. 4A). Nuclear extracts from Meg0l and
Tera-1 cells formed retardation complexes with the -243/-
18 and -538/-238 probes. The identity of proteins inter-
acting at the potential binding sites was assessed using
competitor oligonucleotides for AP2, Sp1, GATA-1 and
NFκB sites and a non-specific unrelated oligonucleotide.
AP2 as well as Sp1 oligonucleotides prevented the forma-
Western blots of human podocalyxin and Sp1 transcription  factor Figure 2
Western blots of human podocalyxin and Sp1 tran-
scription factor. Cell lysates (20 µg) were resolved on 
SDS-7.5% polyacrylamide gels under reducing conditions, 
transferred to PVDF membranes and immunoblotted with 
either 1 µg/ml of anti-podxl or anti Sp1 antibodies. β-Actin 
content was blotted as a control of gel loading. The experi-
ment was repeated three times.BMC Molecular Biology 2006, 7:17 http://www.biomedcentral.com/1471-2199/7/17
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tion of the same protein/DNA complex within the -243/-
18 probe (Fig. 4B), whereas no effect was observed (data
not shown) with any of the other oligonucleotides. No
displacement of the EMSA bands was appreciated with an
antibody against AP2, regardless of the type of nuclear
extract used (Fig. 4B). With the -538/-238 probe no com-
petition was observed with a 100-fold excess of oligonu-
cleotides (data not shown).
We ran supershift assays using nuclear extracts from
Meg0l cells on different probes: "A" probe includes -91/-
68 overlapped Sp1 sites (Sp1-A); "B" probe includes -146/
-128 Sp1 sites (Sp1-B); "C" probe includes -146/-128 and
-167/-140 sites (Sp1-B and Sp1-C), and "D" probe that
only includes -204/-189 Sp1 site (Sp1-D, Fig. 5A). As
shown in Fig. 5B, protein-DNA complexes were formed
with all the probes tested and at least one of the com-
plexes was shifted by anti-Sp1, excepting those in which
probe B were used. Therefore, the binding of nuclear pro-
teins to the Sp1-C site may explain the supershifted com-
plexes observed with "C" probe. When probes with
mutated Sp1 sites were used no supershifts were observed
(Fig. 5B). Similar results were obtained when Tera-1
nuclear extracts were used (data not shown). In agreement
with the EMSA assays, mutations in either Sp1-A, Sp1-C or
Sp1-D sites inhibited the activity of the Podxl promoter by
~50% (Fig. 6) whereas mutation of Sp1-B did not (data
not shown).
Effect of promoter CpG methylation on the cellular 
expression of podxl
DNA methylation has been suggested to play a role in
maintaining the stability of cell differentiation and in reg-
ulating gene transcription [17,18]. It has been recently
reported that the selective demethylation of a promoter
DNA may be a general mechanism required for the repro-
gramming of somatic cell nuclei [19]. DNA sequences rich
in CpG are susceptible of methylation and therefore
silencing the gene expression. Computer analysis of the
5'-flanking region of the Podxl gene with CpGPlot pro-
gram [20] shows the existence of a putative CpG island,
from -607 to the translation start site, containing 27 CpG
dinucleotide sequences. The methylation of cytosines
may control the transcriptional activity through changes
in the binding activity of Sp1 sites. Thus, in order to eluci-
date the possible epigenetic regulation of Podxl we ana-
lyzed the methylation status of individual promoter CpG
sites in cells expressing either high (Tera-1) or low
Gel mobility-shift analysis of DNA-protein complexes using  the human podocalyxin promoter fragment -243/-18 Figure 4
Gel mobility-shift analysis of DNA-protein complexes 
using the human podocalyxin promoter fragment -
243/-18. A) Western blots were performed as described 
under Fig. 2; B) Five µg of nuclear extracts (NE) from Tera-1 
and Meg0l cells were incubated with the probe. Competitive 
gel shift assay was done in the presence of 100-fold molar 
excess of unlabeled double-stranded oligonucleotides corre-
sponding to the pointed out transcription factors consensus 
and unrelated nonspecific (Non Sp) motifs. Antibodies (2 µg) 
for AP2 or non-specific were preincubated with the Tera-1 
and Meg0l NE before the addition of the Podxl probe.
Effect of Sp1 on podocalyxin gene promoter activity in insect  cells Figure 3
Effect of Sp1 on podocalyxin gene promoter activity 
in insect cells. Drosophila-derived SL2 cells were transiently 
cotransfected with 5 µg of pGL3/Podxl-pr constructs and 
with either 0.5 µg of pPAC void plasmid or 0.5 µg of pPAC-
Sp1 plasmid. Luciferase activities were normalized by protein 
concentration and are shown as the fold increases relative to 
the basal activity of void pGL3-basic plasmid (control). Values 
reported in the figure are mean ± SEM of three independent 
experiments in duplicates.BMC Molecular Biology 2006, 7:17 http://www.biomedcentral.com/1471-2199/7/17
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(Meg0l) levels of podxl (Fig. 4A). Genomic DNA of both
cell lines were treated with bisulfite and then amplified by
PCR with the specific primers described under Methods.
Bisulfite changes all the unmethylated cytosines to uracils
and the uracils are PCR-amplified as thymidines, whereas
the methylated cytosines are not modified. As indicated in
Fig. 7, Tera-1 and Meg0l cells showed different patterns of
methylation. In high-podxl expressing cells the promoter
region is unmethylated whereas in low-podxl expressing
cells, Meg0l cells, the promoter is partially methylated.
The main difference was observed in the methylation of
CpG boxes from 23 to 27 (Fig. 7).
The role of methylation in controlling the Podxl gene was
also investigated studying the effects of a demethylating
agent, 5'-aza-2' deoxycitidine (5-azaC), on the podxl
expression. Fig. 8A shows that 5-azaC was unable to
enhance the expression of podxl in HEK293 cells. In con-
trast, a 5-azaC-concentration-dependent increase of podxl
was observed in Meg0l cells. Treatment with 5-azaC did
not modify the Sp1 cellular content (Fig. 8B).
To further assess the influence of CpG methylation on the
promoter activity of Podxl, we methylated promoter frag-
ments in vitro by Sss I followed by their transfection into
HEK293 cells. Fig. 9 shows the results of these experi-
ments using either mock methylated or methylated -111,-
181 and -210 constructs. The in vitro methylation of either
construct by Sss I almost abolished the promoter activity.
Discussion
In this work we have analyzed the structure and function
of the Podxl gene promoter. This protein was originally
described in the podocytes of the epithelial glomerular
cells [1]. Podxl is also present in extra-renal tissues, partic-
ularly in the vascular endothelial and hematopoietic cells.
Moreover, podxl has also been found in tumor cells [21-
23] and its expression has been considered as a good
Identification of Sp1-DNA complexes by supershift assays Figure 5
Identification of Sp1-DNA complexes by supershift assays. A) Different probes were designed as described under 
"Methods" in order to identify functional Sp1 sites in the Podxl promoter. B) Antibodies (2 µg) for Sp1 and non-specific, were 
preincubated with 5 µg of Meg01 nuclear extracts (NE) before the addition of the wild or mutated Sp1-containing Podxl 
probes. BSA (2 µg) was used as a control. An arrow points to the supershifted Sp1 bands.BMC Molecular Biology 2006, 7:17 http://www.biomedcentral.com/1471-2199/7/17
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marker of mieloproliferative disorders [24]. The interest
on podxl has been recently focused on its putative capac-
ity to regulate the intercellular contacts.
The information about the regulation of the Podxl gene is
scarce. The Wilms tumor suppressor factor (WT1) is a
potent regulator of kidney induction and nephrogenesis
[25,26] that controls the expression of Podxl [14]. How-
ever, the WT1 factor is downregulated in all tissues except
in the glomerular epithelial cells where it is expressed
throughout life. Mutations in the WT1 gene are associated
with glomerulosclerosis in patients of Denys Drash syn-
drome indicating the importance of this factor in the renal
function in adulthood. Moreover, nephrogenesis can be
rescued in WTl-null mice by reintroducing the gene [26].
However, regulatory factors other than WT1 in renal or
extra-renal tissues are undefined. The lack of TATA or
CAAT boxes in the Podxl promoter, its high content of
C+Gs and the control by Sp1 sites are typical features of
house-keeping genes. The transcriptional activity of the
progressive 5' deletions of this promoter indicated that its
basic activity was located in the region 66 to -111 nts
increasing as the length of the DNA fragment increased
(Fig. 1). The progressive rise in the promoter activity
directly correlates with the number of recognition sites for
Sp1, suggesting its functional importance. This interpreta-
tion is supported by the absence of transcriptional activity
of the Podxl promoter constructs in insect cells (Dro-
sophila SL2) that lack Sp1 transcription factor and the ini-
tiation of transcriptional activity by cotransfection of an
expression plasmid encoding Sp1 (Fig. 3). Despite differ-
ences in endogenous content of podxl, the activity of the
Podxl promoter was similar whether Tera-1, HepG2 or
HEK293 cells were used in the transfection experiments
(Fig. 1). This observation may find an explanation in the
similar levels of Sp1 factor found in these cells (Fig. 2).
The nucleotide competition assays gave positive results
for Sp1 and AP2 whether nuclear extracts from Tera-1 or
from Meg0l cells were used; however, no supershift was
observed when monoclonal against AP2 was utilized (Fig.
4B). The competitive effect of AP2 oligonucleotide in the
formation of protein-DNA complexes may be related to
the sequence similarities between Sp1 and AP2 recogni-
tion sites. The EMSA studies indicate that overlapped Sp1
sites -167/-140 nts, -91/-68 nts and -204/-189 nts were
able to interact with Sp1, since some of the formed com-
plexes were supershifted by anti-Sp1 Ab and their forma-
tion was-prevented by mutating the recognition sites.
Moreover, the mutation of the Sp1 sites reduced the tran-
scriptional activity of Podxl.
DNA methylation is associated with malignant transfor-
mation [27] of cells but knowledge of the epigenetic
events in the initiation and progression of human cancer
is limited. The abundant number of CpG islands in the
Podxl promoter suggested that methylation could be a
regulatory factor. Transcriptional repression of methyl-
ated genes may be mediated by the binding of certain pro-
teins, such as MeCP2 [28-30]. Moreover, DNA
methylation may interfere with the binding of Sp1 to
DNA [31].
Demethylation of the promoter DNA may be a necessary
step in the epigenetic reprogramming of somatic cell
nuclei [19]. Demethylation is a selective process, operat-
ing only on the promoter, but not on enhancers; both a
putative Sp1/Sp3 and a GGGAGGG binding site are
required for demethylation and the initiation of transcrip-
Effect of mutating the Sp1 recognition sites on the activity of podocalyxin promoter Figure 6
Effect of mutating the Sp1 recognition sites on the activity of podocalyxin promoter. Transient transfections were 
performed into HEK293 cells. Results represent mean ± SEM from four independent experiments performed in duplicates. 
Promoter activity of each transfection was expressed as a ratio of luciferase/renilla activities. Data are expressed as percent of 
the maximal activity of the -210 construct *p < 0.05 vs. non Sp1-site-mutated construct.BMC Molecular Biology 2006, 7:17 http://www.biomedcentral.com/1471-2199/7/17
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State of methylation of CpG dinucleotides in the human podocalyxin promoter Figure 7
State of methylation of CpG dinucleotides in the human podocalyxin promoter. A) Schematic representation of a 
fragment of the Podxl-pr comprising 208 nts upstream the transcription start site (indicated with an arrow) and the 5'UTR. 
Grey boxes denote the positions of CpG dinucleotides. Underlined nts indicate Sp1 recognition sites. B) Genomic DNA from 
Tera-1 or Meg0l cells were extracted and subjected to bisulfite treatment, PCR amplification and DNA sequencing as 
described in Methods. CpG sites are numbered from 1 to 27 relative to the transcription start site. Three bisulfite treatments 
were performed. Data is expressed as % of methylation, calculated as percentage of conserved C in at least 10 clones obtained 
after each bisulfite treatment.BMC Molecular Biology 2006, 7:17 http://www.biomedcentral.com/1471-2199/7/17
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tion. We analyzed whether methylation of the Podxl pro-
moter could influence its transcriptional activity: firstly,
using demethylating agents in vivo and in second place by
studying the state of methylation of the CpG islands in
cultured cells expressing different amounts of Podxl. As a
demethylating agent we used 5-azaC, structural analog of
citidine, that inactivates methyltransferases upon its
incorporation into DNA with the result of activation of
DNA transcription. This inhibitor has been used success-
fully as a therapeutic agent in acute myeloid leukemia and
myelodysplastic syndrome [32]. In our case, treatment of
low podxl-expressing cells with 5-azaC induced a dose-
dependent increase on podxl content whereas no effects
could be detected in cells, like HEK293, expressing higher
levels of podxl. However, the reported effect of 5-azaC in
inducing the activity of genes in the absence of methyla-
tion of CpG islands indicates that these results should be
taken cautiously [33]. The treatment with 5-azaC may sta-
bilize and increase the endogenous content of Sp1 [34]
nevertheless in our case 5-azaC did not modify Sp1 cellu-
lar content. On the other hand, bisulfite treatment of
genomic DNA from high (Tera-1) or low (Meg0l) podxl-
expressing cells showed a direct relationship between the
degree of methylation of the promoter region and expres-
sion of podxl. The influence of the CpG methylation was
further assessed by treating the promoter constructs -111,-
181 and -210 with the methylase Sss I prior to transfection
into HEK293 cells. These results add further evidence
indicating that methylation may inhibit the activity of the
Podxl promoter.
Conclusion
The in vitro transcription of the human Podxl promoter is
dependent on the presence of Sp1 sites. This conclusion is
supported by the following observations: 1) No activity
was detected when the promoter constructs were trans-
fected into Sp1-lacking insect cells in which the transcrip-
tion was initiated by cotransfection of an Sp1 expression
plasmid; 2) The promoter function was impaired by
mutation of the Sp1 sites.
Methylation of the CpG promoter islands seems to be a
significant regulatory mechanism in controlling the tran-
scription of Podxl. The latter observation may provide an
explanation for the different rates of podxl expression in
different tissues of the organism.
Methods
Materials
Cell culture media was from GIBCO, Invitrogen (Scot-
land, UK). Fetal bovine serum was from ICN Biochemi-
cals (Irvine, CA, USA). Restriction endonucleases were
obtained from Roche Diagnostics, SL (Barcelona, Spain).
Antibody against β-actin was from Sigma RBI (Madrid,
Spain); mAbs against Sp-1 (sc-420x and sc-420) or AP2
(sc-25343x) were from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Mouse mAb against human podxl (clone
"3D3") was a generous gift of Dr. David B. Kershaw from
the Department of Pediatrics, University of Michigan. [α-
32P]dCTP was from Amersham Iberica (Spain). The Dual-
Luciferase Reporter Assay System, pGL3-basic vector and
Wizard DNA Clean-Up System were from Promega (Mad-
ison, WI). Sss I (CpG) methylase was from New England
Biolabs (Beverly, MA). Oligonucleotides were obtained
from Invitrogen (Paisley, UK). All other reagents were of
analytical grade and were purchased from commercial
sources.
Construction of reporter plasmids
A 1528-bp DNA fragment was amplified by PCR from
human genomic DNA using the primers Podxl-pr -1297/-
1275 (5'-GAGCGGGGGAGGGGAAAGGAA-3') and
Podxl-pr 231/208 (5'-GGAGCAGGTGGCTGCGGTGC-3')
as sense and antisense oligonucleotides, respectively. The
PCR product was subcloned directly into a T vector (Topo
TA cloning, Invitrogen) to introduce Xho I and Hind III
restriction sites in 5' and 3' ends, respectively. The Xho I/
Hind III (-1297/231) fragment was subcloned into Xho I/
Expression of human podocalyxin in HEK293 and Meg0l cells  treated with 5-AzaC Figure 8
Expression of human podocalyxin in HEK293 and 
Meg0l cells treated with 5-AzaC. Cells were treated 
with 5-AzaC for 48 hrs. Cell lysates were resolved on SDS-
7.5% polyacrylamide gels under non-reducing conditions, 
transferred to PVDF membranes and immunoblotted with A) 
1 µg/ml of anti-podocalyxin mAb and B) 1 µg/ml of anti-Sp1 
mAb. β-Actin was blotted as a loading control. The experi-
ment was repeated three times.BMC Molecular Biology 2006, 7:17 http://www.biomedcentral.com/1471-2199/7/17
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Hind III sites of pGL3-basic to yield the construct -1297.
Construct -1234 was produced by partial digestion with
EcoR I and religation of the -1297 construct. Constructs -
111, -181, -210, -364, -851, and -1108 were obtained by
PCR amplification from construct -1297 using as anti-
sense primer Podxl-pr 231/212 (5'-GCCTCGAGCAGGT-
GGCTGCGGT-3', underlined bp were mutated to generate
a Xho I site) and one of the following sense primers:
Podxl-pr -111/-93 (5'-TGGCGAGCTCCTGGGGGAGGG-
3'), Podxl-pr -181/-161 (5'-GCTCAGAGCTCACG-
GCCCAGCG-3'), Podxl-pr -210/-189 (5'-GTCGAGCTC-
CAGGGCGGAGTTTC-3'), Podxl-pr -364/343 (5'-
GGGAGCTCGCCGGGCCCACTTA-3'), Podxl-pr -851/-
830 (5'-CTGAGCTCAGAGGCAGGTTTGC-3'), Podxl-pr -
1108/-1087 (5'-TTGAGCTCCCCAACAACCCCCT-3').
Underlined nucleotides in sense oligonucleotides were
mutated to generate Sac I sites. pGL3-constructs with
mutated Sp1 sites were obtained by PCR from DNA tem-
plate and antisense oligonucleotide mentioned above and
the following sense primers: Podxl-pr -90/-79 mutSp1-A
(5'-GAGCTCCGGTGGTGGGGGTGGGGG-3'), Podxl-pr -
146/-126 mutSp1-B (5'-CAGCTCCGGCCTTGCCCG-
GCC-3'), Podxl-pr -178/-150 mutSp1-C (5'-TCATTGT-
TCAAAGCCCAGAGCCCACCCAG-3'), Podxl-pr -207/-
184 mutSp1-C (5'-GAGCTCCAGGTTGGAGTTTCC-3').
Underlined nucleotides show mutated nucleotides. The
resulting PCR products were subcloned into a T vector and
sequenced in an ABI PRISM 3100 Genetic Analyzer
(Applied Biosystems, Foster City, CA). The TOPO con-
structs were digested with Sac I and Xho I and ligated to
the Sac I and Xho I sites of pGL3-basic plasmid. Restric-
tion enzyme digestion, sequence analysis, or both were
used to verify the constructions. A computer analysis for
potential binding sites on DNA sequences was carried out
with the TFSEARCH program [19].
Cell lines
HepG2 (hepatoma cells) and HEK293 (human embry-
onic kidney cells) were grown in DMEM, Tera-1 (testes
embryonal carcinoma cells) in McCoy medium, Meg0l
(human megakaryoblastic cells) in RPMI medium, all
obtained from GIBCO (Madrid, Spain), and Drosophila
Schneider's SL2 cells in Schneider's insect medium
(Sigma, Madrid, Spain). Culture media were supple-
mented with 10% fetal bovine serum. SL2 cells were
grown at 25°C and all other cell lines at 37°C.
Transient transfection procedure
HepG2, Tera-1 and HEK293 cells were transfected by the
calcium phosphate precipitation technique in 60-mm
dishes with 2 µg of pGL3/Podxl constructs described
above and 0.5 µg of phRL-cmv plasmid for transfection
efficiency correction. For negative and positive controls of
transfection, pGL3-basic and the 3TP promoter-luciferase
construct (p3TP-lux), containing three copies of the TPA
response element from the human collagenase promoter
plasmids were used. SL2 cells were cotransfected with
Effect of in vitro DNA methylation on the podocalyxin promoter-driven luciferase expression Figure 9
Effect of in vitro DNA methylation on the podocalyxin promoter-driven luciferase expression. Transient transfec-
tions were performed in HEK293 cells. Results represent mean ± SEM from three independent experiments performed in 
duplicates. Promoter activity of each transfection was expressed as a ratio of luciferase/renilla activities. Data are expressed as 
arbitrary units calculated as fold increases over void pGL-3 enhancer vector activity, which is assigned a value of 1.0. *p < 0.05 
vs. mock methylated control.BMC Molecular Biology 2006, 7:17 http://www.biomedcentral.com/1471-2199/7/17
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pGL3/Podxl constructs and either pPAC-Sp1 that
expresses human Sp1 driven by the Drosophila actin pro-
moter, or the control vector pPacO, containing only the
Drosophila  actin promoter. The amount of transfected
DNA was maintained constant with void plasmid. Either
6 h (HEK293 and Tera-1 cells) or 16 h (HepG2 and SL2
cells) after transfection, the medium was changed and
cells were incubated for another 48 h. The luciferase activ-
ity was determined using the Dual-Luciferase Reporter
Assay System (Promega, Madison, WI, USA) in cell
extracts prepared according to manufacturer recommen-
dations in a TD-20/20 luminometer (Turner Designs,
Sunnyvale, CA, USA). Luciferase activities were normal-
ized by Renilla luciferase activity, except for SL2 experi-
ments that were normalized by the protein concentration
that was measured using a Bradford protein assay kit (Bio-
Rad Laboratories, Inc., Richmond, CA, USA).
Gel retardation assay
DNA probes were prepared by PCR amplification from
the -1296 construct. The following sense and antisense
primers were used: for -243/-18 probe: Podxl-pr -243/-
223 (5'-CCAAGGCTCGAGGCCGCCGG-3') and Podxl-pr
-18/-38 (5'-CACTGGCGGCTGCGGCTACTC-3'); for-538/
-238 probe: Podxl-pr-538/-518 (5'-GGGCTCGAGAG-
GCAGGTGAAT-3') and Podxl-pr -238/-258 (5'-CCTT-
GGGGGGCTGTGTGTGCG-3'), for A probe: Podxl-pr -
111/-93 and Podxl-pr -18/-38, for mutSp1-A probe:
Podxl-pr -90/-79 mutSp1-A and Podxl-pr -18/-38, for B
probe: Podxl-pr -146/-136 (5'GAGCTCCG-
GCCCCGCCCGGCC-3') and Podxl-pr -94/-114 (5'CTC-
GAGCAGGAGCCCGCCAGC-3'); for mutSp1-B probe:
Podxl-pr-146/-126 mutSp1-B and Podxl-pr -94/-114; for
C probe: Podxl-pr-181/161 and Podxl-pr -94/-114; for
mutSp1-C probe: hPodxl-pr -178/-150 mutSp1-C and
Podxl-pr -94/-114; for D probe: Podxl-pr -210/-189 and
Podxl-pr -150/-178mutSp1-C (5'-CTGGGTTGGTTCT-
GGGCTTTGAATGA-3'); for mutSp1-D probe: Podxl-pr -
207/-184 mutSp1-D and Podxl-pr -150/-178mutSp1-C.
All the probes were labeled using the Klenow fragment of
Escherichia coli polymerase and [32P]dCTP. Nuclear
extracts from Tera-1 and Meg0l cells were prepared
according to standard protocols. Nuclear extracts (5 µg)
were preincubated for 15 min at 4°C in 25 µL-binding
reaction containing: 10 mM Tris/HCl pH 7.5, 50 mM
NaCl, 2.5 mM MgC12, 4% glycerol, 0.5 mM dithiothreitol
and 3 µg poly(dI-dC). After adding ~30 pg of labeled
DNA, the mixture was incubated for 30 min at room tem-
perature, and the complexes formed resolved on a 4%
nondenaturing polyacrylamide gel in 0.5 × TBE buffer.
Gels were run at 150 V at room temperature, dried and
exposed at -80°C to an X-ray film.
For competition assays, 100-fold molar excess of unla-
beled double stranded DNA consensus sequences of bind-
ing sites for AP2, Sp1, NFkB and GATA transcription
factors were included in the binding reaction. These DNA
fragments were prepared by hybridization of sense and
antisense oligonucleotides of the following sequences: 5'-
GATCGAACTGACCGCCCGCGGCCC-3' for AP2, 5'-
ATTCGATCGGGGCGGGGCGAG-3' for Sp1, 5'-AGTT-
GAGGGGACTTTCCCAGGC-3' for NFkB and 5'-CACTT-
GATAACAGAAAGTGATAACTCT-3' for GATA DNA
binding sites. As nonspecific competitor, an unrelated
DNA fragment of similar size and base composition was
used. In supershift experiments, nuclear extracts were pre-
incubated with either mAbs against Sp1, AP2 or nonspe-
cific antibodies, prior to incubation with the radiolabeled
probes.
In Vitro methylation reactions
To examine the effect of CG methylation on the promoter
activity, Podxl promoter constructs -111,-181,-210 were
mock methylated or methylated by Sss I methylase in the
absence or presence of S-adenosylmethionine. The status
of methylation was determined by digestion with the
restriction enzyme Hpa II. Mock-methylated or Sss I
methylated plasmids were isolated from 1% agarose gel
using Gel Purification Kit from Qiagen.
Western blot analysis
For western blot analysis, cells were lysed in 100 µl of
phosphate buffered saline containing 1% Triton X-100,
0.1% SDS, 2 mM phenylmethylsulfonyl fluoride, 2 mM
EDTA, and 1% of protease inhibitors cocktail. Cellular
extracts were resolved by SDS-PAGE and transferred to
PVDF membranes. The membranes were incubated with
mAb against Sp1 (Sta Cruz sc-420) or Podxl (3D3) and
subsequently with the horseradish peroxidase-conjugated
secondary antibody (BioRad, Madrid, Spain). β-Actin was
blotted in order to normalize the amount of lysate in the
experiments. To develop the blots we use the ECL reagent.
Treatment of cells with 5-Aza-2 deoxycytidine
The cells were treated with 5-azaC at a final concentration
of 1 µM or 5 µM for 7 days. The medium was changed
every second day. Negative controls were treated in the
same manner without 5-azaC. Then, cells were lysed for
western blot analysis and blotted with the mAb anti-Podxl
primary antibody (3D3).
Bisulfite modification of genomic DNA
To release small fragments of genomic DNA of Meg0l and
Tera-1 cells we digested with restriction enzymes that
don't cleave the CpG region of the Podxl-pr. Digested
genomic DNAs were denatured, modified by bisulfite,
purified, and desulphonated according to Herman et al
[35]. Degenerated primers for PCR were designed to
amplify the region between -618 to +368 (Podxl-pr -618/
-592 5'-GGTGAAGGAGTGAATTAGTC/TC/TAGC/TTTG-3'BMC Molecular Biology 2006, 7:17 http://www.biomedcentral.com/1471-2199/7/17
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and Podxl-pr 368/343 5'-AGAATGGTGAGTGGC/TC/
TGGC/TC/TTGGGTT-3). The PCR fragments were purified
by the JetQuick Purification Kit (Genomed) and
sequenced.
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